COMPASS THERAPEUTICS INC (CMPX) Forecast, Price Target & Analyst Ratings
NASDAQ:CMPX • US20454B1044
5.44 USD
-0.09 (-1.63%)
Last: Mar 6, 2026, 01:35 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for COMPASS THERAPEUTICS INC (CMPX).
Forecast Snapshot
Consensus Price Target
$14.37
+ 164.20% Upside
Next Earnings Forecast
Release DateMay 6, 2026
PeriodQ4 / 2025
EPS Estimate-$0.10
Revenue Estimate
ChartMill Buy Consensus
87.62%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$14.37
Upside
+ 164.20%
From current price of $5.44 to mean target of $14.37, Based on 21 analyst forecasts
Low
$8.08
Median
$12.24
High
$31.50
Price Target Revisions
1 Month
9.04%
3 Months
10.71%
Price Target Summary
21 analysts have analysed CMPX and the average price target is 14.37 USD. This implies a price increase of 164.2% is expected in the next year compared to the current price of 5.44.
The average price target has been revised upward by 10.71% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
87.62%
CMPX was analyzed by 21 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about CMPX.
In the previous month the buy percentage consensus was at a similar level.
CMPX was analyzed by 21 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-06 | D. Boral Capital | Maintains | Buy -> Buy |
| 2026-01-05 | William Blair | Initiate | Outperform |
| 2025-12-03 | Citizens | Initiate | Market Outperform |
| 2025-12-03 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-12-03 | Canaccord Genuity | Initiate | Buy |
| 2025-11-05 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-06 | LifeSci Capital | Initiate | Outperform |
| 2025-08-12 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-12 | Guggenheim | Maintains | Buy -> Buy |
| 2025-07-01 | Raymond James | Reiterate | Outperform |
| 2025-05-09 | Guggenheim | Maintains | Buy -> Buy |
| 2025-04-28 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-22 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-04-21 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-02 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2025-04-02 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-04-01 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-02-27 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-02-25 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-02-24 | Guggenheim | Initiate | Buy |
| 2025-02-19 | Piper Sandler | Initiate | Overweight |
| 2025-02-10 | Jefferies | Maintains | Buy -> Buy |
| 2025-01-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 6, 2026
PeriodQ4 / 2025
EPS Estimate-$0.10
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q12.47%
Number of Analysts17
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
4.73%
Next Earnings Summary
CMPX is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.1 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 850K | -100.00% | 7.734M | 71.995M 830.89% | 220.07M 205.67% | 366.16M 66.38% | 573.7M 56.68% | 996.62M 73.72% | 1.453B 45.79% | 1.973B 35.79% | |||
| EBITDA YoY % growth | -40.88M 49.72% | -49.664M -21.49% | -56.036M -12.83% | -78.576M -40.22% | -90.392M -15.04% | -74.511M 17.57% | -16.463M 77.91% | 28.325M 272.05% | 123.95M 337.60% | 167.63M 35.24% | 211.1M 25.93% | 226.52M 7.30% | |
| EBIT YoY % growth | -41.66M 49.12% | -50.363M -20.89% | -56.625M -12.43% | -74.453M -31.48% | -83.566M -12.24% | -94.532M -13.12% | 11.18M 111.83% | 133.04M 1,089.98% | 298.99M 124.74% | 729.02M 143.83% | 1.129B 54.87% | 1.578B 39.77% | |
| Operating Margin | N/A | N/A | -6,661.76% | N/A | -1,080.50% | -131.30% | 5.08% | 36.33% | 52.12% | 73.15% | 77.70% | 79.98% | |
| EPS YoY % growth | -0.37 69.70% | -0.34 8.11% | -0.37 -8.82% | -0.44 -19.15% | -0.46 -3.31% | -0.50 -10.26% | 0.08 115.23% | 0.58 658.67% | 1.32 127.10% | 3.16 139.57% | 4.40 39.32% | 5.87 33.51% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.10 12.47% | -0.11 6.33% | -0.11 19.29% | -0.11 -38.83% | -0.11 -18.11% | -0.07 35.12% | -0.06 45.84% | -0.03 74.29% | -0.03 74.44% | 0.02 132.17% | 0.04 165.00% | 0.04 232.14% |
| Revenue Q2Q % growth | 2.38M | 6.477M | 3.06M | 10.2M 328.57% | 20.563M 217.48% | N/A | N/A | N/A | ||||
| EBITDA Q2Q % growth | -22.787M -42.55% | -19.156M -10.15% | -19.768M 2.79% | -20.451M -38.98% | -20.839M 8.55% | -21.247M -10.92% | -19.176M 2.99% | -13.841M 32.32% | -5.947M 71.46% | N/A | N/A | N/A |
| EBIT Q2Q % growth | -17.243M -4.04% | -20.333M -22.41% | -20.08M 4.68% | -21.047M -33.07% | -23.786M -37.94% | -21.257M -4.54% | -19.186M 4.45% | -13.852M 34.19% | -5.957M 74.96% | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-10.72%
EPS Next 5 Year
28.97%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
331.62%
Revenue Next 5 Year
232.92%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-10.13%
EBIT Next 5 Year
20.19%
COMPASS THERAPEUTICS INC / CMPX Forecast FAQ
Can you provide the average price target for COMPASS THERAPEUTICS INC stock?
21 analysts have analysed CMPX and the average price target is 14.37 USD. This implies a price increase of 164.2% is expected in the next year compared to the current price of 5.44.
Can you provide the upcoming earnings date for COMPASS THERAPEUTICS INC?
COMPASS THERAPEUTICS INC (CMPX) will report earnings on 2026-05-06.
Can you provide the consensus estimates for COMPASS THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of COMPASS THERAPEUTICS INC (CMPX) is -0.1 USD and the consensus revenue estimate is 0 USD.
How many analysts cover COMPASS THERAPEUTICS INC (CMPX) stock?
The number of analysts covering COMPASS THERAPEUTICS INC (CMPX) is 21.